Gynecologic Care and Contraception in the Medically Complex Adolescent


When caring for adolescents and young women with chronic illnesses, it is important to address routine gynecologic care and your patient’s contraceptive needs to ensure her optimal health and avoid putting an unplanned pregnancy at risk for serious health effects to both the mother and/or the fetus. This chapter will review what special considerations need to be employed in routine gynecologic care for medically complex paients including Pap smear screening, STI screening, and HPV vaccination. In addition, this chapter will discuss special considerations to address your patient’s contraceptive needs. This will include how the chronic illness and the medications used to treat it interact with contraception and why it is important to consider the risk of pregnancy to your patient’s health and that of the fetus, in addition to issues of teratogenicity, thrombosis, contraceptive efficacy, continuation rates, and interactions with contraception and chronic illness medications.


Routine gynecologic care Pap smear screening STI screening HPV vaccination 


  1. 1.
    ACOG Practice Bulletin Number 157: cervical cancer screening and prevention. Obstet Gynecol. 2016;127(1):e1–20.Google Scholar
  2. 2.
    Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed 14 May 2016.
  3. 3.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2009. Atlanta: U.S. Department of Health and Human Services; 2010.Google Scholar
  4. 4.
    Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423.CrossRefGoogle Scholar
  5. 5.
    Klumb EM, Araújo ML Jr, Jesus GR, et al. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol. 2010;16:153.CrossRefGoogle Scholar
  6. 6.
    Origoni M, Stefani C, Dell’Antonio G, et al. Cervical Human Papillomavirus in transplanted Italian women: a long-term prospective follow-up study. J Clin Virol. 2011;51(4):250–4.CrossRefGoogle Scholar
  7. 7.
    Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283(8):1031.CrossRefGoogle Scholar
  8. 8.
    Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2007;103(3):631–6.CrossRefGoogle Scholar
  9. 9.
    Phipps W, Stanley H, Kohn R, Stansell J, Klausner JD. Syphilis, chlamydia, and gonorrhea screening in HIV-infected patients in primary care, San Francisco, California, 2003. AIDS Patient Care STDS. 2005;19(8):495.CrossRefGoogle Scholar
  10. 10.
    CDC, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, the National Minority AIDS Council, and Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV prevention with adults and adolescents with HIV in the United States, 2014.
  11. 11.
    Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant. 2013;13(9):2411–7. Epub 2013 Jul 9.CrossRefGoogle Scholar
  12. 12.
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1.PubMedGoogle Scholar
  13. 13.
    Robinson CL, Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years – United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(4):86–7.CrossRefGoogle Scholar
  14. 14.
    Guazzelli CAF, Torloni MR, Sanches TF, et al. Contraceptive counseling and use among 197 female kidney transplant recipients. Transplantation. 2008;86:669.CrossRefGoogle Scholar
  15. 15.
    Medical eligibility criteria for contraceptive use. 4th ed. World Health Organization. 2015. Accessed 25 April 2016.
  16. 16.
    U.S. Medical Eligibility Criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use. 4th ed. Accessed 25 April 2016.
  17. 17.
    Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550–8.CrossRefGoogle Scholar
  18. 18.
    Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2539–49.CrossRefGoogle Scholar
  19. 19.
    Choojitarom K, Verasertniyom O, Totemchokchyakarn K, et al. Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol. 2008;27:345–51.CrossRefGoogle Scholar
  20. 20.
    Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus–a meta-analysis. Lupus. 1997;6:467–73.CrossRefGoogle Scholar
  21. 21.
    Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med. 2016;374(9):843–85.CrossRefGoogle Scholar
  22. 22.
    Steinkellner A, Chen W, Denison SE. Adherence to oral contraception in women on Category X medications. Am J Med. 2010;123(10):929.CrossRefGoogle Scholar
  23. 23.
    Hatcher RA. Contraceptive technology. 20th ed. Bridging the Gap Communications; 2011.Google Scholar
  24. 24.
    Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397.CrossRefGoogle Scholar
  25. 25.
    Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012;120(6):1298–305.CrossRefGoogle Scholar

Suggested Educational Reading, References, and Policies

  1. The American Congress of Obstetricians and Gynecologists. Practice Bulletin Number 157: cervical cancer screening and prevention. Obstet Gynecol. 2016;127(1):e1–20.CrossRefGoogle Scholar
  2. Medical eligibility criteria for contraceptive use. 5th Edition. World Health Organization.
  3. U.S. Medical Eligibility Criteria for contraceptive use.
  4. 2015 Sexually transmitted diseases treatment guidelines. Centers for Disease Control and Prevention.

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Division of Adolescent Medicine, Department of PediatricsChildren’s Hospital at Montefiore, Albert Einstein College of MedicineBronxUSA

Personalised recommendations